©The Author(s) 2025.
World J Clin Oncol. Nov 24, 2025; 16(11): 111983
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111983
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111983
Figure 2 Mutation frequencies in accelerated-phase chronic myeloid leukemia and blast crisis chronic myeloid leukemia patient samples.
ACIN1: Apoptotic chromatin condensation inducer 1; AP-CML: Accelerated-phase chronic myeloid leukemia; BC-CML: Blast crisis chronic myeloid leukemia; BCR: Breakpoint cluster region; BRCA: Breast cancer susceptibility gene; EGFR: Epidermal growth factor receptor; ERG: ETS-related gene; NDRG2: N-myc downstream-regulated gene 2; NF1: Neurofibromatosis type 1; RPTOR: Regulatory associated protein of mechanistic target of rapamycin complex 1; STAB1: Stabilin 1.
- Citation: AlGarni A, Alanazi N, AlMukhaylid S, Alqahtani S, Almasoudi H, Samir Taleb Y, Alkhamis N, Shaheen S, Haji Siyal A, Aleem A, Naeem R, Shammas MA, Saglio G, Alroweilly D, Hussain A, Iqbal Z. Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing. World J Clin Oncol 2025; 16(11): 111983
- URL: https://www.wjgnet.com/2218-4333/full/v16/i11/111983.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i11.111983